{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:19:01Z","timestamp":1793380741996,"version":"4.5.0"},"reference-count":101,"publisher":"Bentham Science Publishers Ltd.","issue":"13","funder":[{"DOI":"10.13039\/501100004763","name":"Inner Mongolia Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2023LHMS08045"],"award-info":[{"award-number":["2023LHMS08045"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202008210289"],"award-info":[{"award-number":["202008210289"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060624"],"award-info":[{"award-number":["82060624"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>SARS-CoV-2 has swept the world in recent years, triggering a global\nCOVID-19 with a tremendous impact on human health and public safety. Similar to\nother coronaviruses, the six-helix bundle(6-HB) is not only a core structure driving the\nfusion of the SARS-CoV-2 envelope with the host cell membrane, but also the target of\nfusion inhibitors. The sequences from the HR1 or HR2 regions composing 6-HB are\nthus the original primary structures for the development of peptide-based fusion inhibitors.\nThis review summarized the structure-activity relationship of the SARS-CoV-2 6-\nHB, analyzed the design methods and functional characteristics of peptide-based fusion\ninhibitors that contain different regions of HRs, and provided an outlook on the cutting-\nedge approaches for optimal modification of lead compounds (pan-coronavirization,\nchemical modification, superhelical construction, etc). We hope that this review will provide\nresearchers with a comprehensive understanding of the state-of-art research\nprogress on both 6-HB and peptide-based fusion inhibitors of SARS-CoV-2, and provide\nsome new insights for the development of antiviral drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673265694231113061842","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T06:27:06Z","timestamp":1701239226000},"page":"2524-2546","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Structure and Function of the SARS-CoV-2 6-HB Fusion Core and Peptide-based Fusion Inhibitors: A Review"],"prefix":"10.2174","volume":"32","author":[{"given":"Guodong","family":"Liang","sequence":"first","affiliation":[{"name":"Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of\nPharmacy, Inner Mongolia Medical University, Huhhot, 010110, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Astbury Centre for Structural\nMolecular Biology, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK"},{"name":"School of Chemistry,\nUniversity of Leeds, Woodhouse Lane, Leeds LS2 9JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of\nPharmacy, Inner Mongolia Medical University, Huhhot, 010110, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory for Candidate Drug Design and Screening Based on Chemical Biology, College of\nPharmacy, Inner Mongolia Medical University, Huhhot, 010110, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiya","family":"Na","sequence":"additional","affiliation":[{"name":"College of Life Sciences, Inner Mongolia\nAgricultural University, Hohhot, 010018, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"Su S.","year":"2016","unstructured":"Su S.; Wong G.; Shi W.; Liu J.; Lai A.C.K.; Zhou J.; Liu W.; Bi Y.; Gao G.F.; Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol  2016,24(6),490-502","journal-title":"Trends Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"671263","DOI":"10.3389\/fmolb.2021.671263","volume":"8","author":"Mei M.","year":"2021","unstructured":"Mei M.; Tan X.; Current strategies of antiviral drug discovery for COVID-19. Front Mol Biosci  2021,8,671263","journal-title":"Front Mol Biosci"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","volume":"55","author":"Lai C.C.","year":"2020","unstructured":"Lai C.C.; Shih T.P.; Ko W.C.; Tang H.J.; Hsueh P.R.; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents  2020,55(3),105924","journal-title":"Int J Antimicrob Agents"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","volume":"612","author":"Stein S.R.","year":"2022","unstructured":"Stein S.R.; Ramelli S.C.; Grazioli A.; Chung J.Y.; Singh M.; Yinda C.K.; Winkler C.W.; Sun J.; Dickey J.M.; Ylaya K.; Ko S.H.; Platt A.P.; Burbelo P.D.; Quezado M.; Pittaluga S.; Purcell M.; Munster V.J.; Belinky F.; Ramos-Benitez M.J.; Boritz E.A.; Lach I.A.; Herr D.L.; Rabin J.; Saharia K.K.; Madathil R.J.; Tabatabai A.; Soherwardi S.; McCurdy M.T.; Babyak A.L.; Perez Valencia L.J.; Curran S.J.; Richert M.E.; Young W.J.; Young S.P.; Gasmi B.; Sampaio De Melo M.; Desar S.; Tadros S.; Nasir N.; Jin X.; Rajan S.; Dikoglu E.; Ozkaya N.; Smith G.; Emanuel E.R.; Kelsall B.L.; Olivera J.A.; Blawas M.; Star R.A.; Hays N.; Singireddy S.; Wu J.; Raja K.; Curto R.; Chung J.E.; Borth A.J.; Bowers K.A.; Weichold A.M.; Minor P.A.; Moshref M.A.N.; Kelly E.E.; Sajadi M.M.; Scalea T.M.; Tran D.; Dahi S.; Deatrick K.B.; Krause E.M.; Herrold J.A.; Hochberg E.S.; Cornachione C.R.; Levine A.R.; Richards J.E.; Elder J.; Burke A.P.; Mazzeffi M.A.; Christenson R.H.; Chancer Z.A.; Abdulmahdi M.; Sopha S.; Goldberg T.; Sangwan Y.; Sudano K.; Blume D.; Radin B.; Arnouk M.; Eagan J.W.; Palermo R.; Harris A.D.; Pohida T.; Garmendia-Cedillos M.; Dold G.; Saglio E.; Pham P.; Peterson K.E.; Cohen J.I.; de Wit E.; Vannella K.M.; Hewitt S.M.; Kleiner D.E.; Chertow D.S.; SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature  2022,612(7941),758-763","journal-title":"Nature"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S0140-6736(22)00327-0","volume":"399","author":"Menni C.","year":"2022","unstructured":"Menni C.; Valdes A.M.; Polidori L.; Antonelli M.; Penamakuri S.; Nogal A.; Louca P.; May A.; Figueiredo J.C.; Hu C.; Molteni E.; Canas L.; \u00d6sterdahl M.F.; Modat M.; Sudre C.H.; Fox B.; Hammers A.; Wolf J.; Capdevila J.; Chan A.T.; David S.P.; Steves C.J.; Ourselin S.; Spector T.D.; Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID. Study Lancet  2022,399(10335),1618-1624","journal-title":"Study Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/jmv.27561","volume":"94","author":"Mohapatra R.K.","year":"2022","unstructured":"Mohapatra R.K.; Sarangi A.K.; Kandi V.; Azam M.; Tiwari R.; Dhama K.; Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: Current global scenario. J Med Virol  2022,94(5),1780-1783","journal-title":"J Med Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"De Clercq E.","year":"2016","unstructured":"De Clercq E.; Li G.; Approved antiviral drugs over the past 50 years. Clin Microbiol Rev  2016,29(3),695-747","journal-title":"Clin Microbiol Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e00014-22","DOI":"10.1128\/cmr.00014-22","volume":"35","author":"Zhou H.","year":"2022","unstructured":"Zhou H.; M\u00f8hlenberg M.; Thakor J.C.; Tuli H.S.; Wang P.; Assaraf Y.G.; Dhama K.; Jiang S.; Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron Variant. Clin Microbiol Rev  2022,35(3),e00014-22","journal-title":"Clin Microbiol Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","volume":"551","author":"Seyed Hosseini E.","year":"2020","unstructured":"Seyed Hosseini E.; Riahi Kashani N.; Nikzad H.; Azadbakht J.; Hassani Bafrani H.; Haddad Kashani H.; The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology  2020,551,1-9","journal-title":"Virology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","volume":"9","author":"Frediansyah A.","year":"2021","unstructured":"Frediansyah A.; Tiwari R.; Sharun K.; Dhama K.; Harapan H.; Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health  2021,9,90-98","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/0929867328666210511015808","volume":"29","author":"Pu J.","year":"2022","unstructured":"Pu J.; Zhou J.T.; Liu P.; Yu F.; He X.; Lu L.; Jiang S.; Viral entry inhibitors targeting six-helical bundle core against highly pathogenic enveloped viruses with class i fusion proteins. Curr Med Chem  2022,29(4),700-718","journal-title":"Curr Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-981-16-8702-0_6","volume":"1366","author":"Wang H.","year":"2022","unstructured":"Wang H.; Wang C.; Peptide-Based Dual HIV and coronavirus entry inhibitors. Adv Exp Med Biol  2022,1366,87-100","journal-title":"Adv Exp Med Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.2174\/1389201024666230330083640","volume":"24","author":"Na H.","year":"2023","unstructured":"Na H.; Liang G.; Lai W.; Isopeptide bond bundling superhelix for designing antivirals against enveloped viruses with class i fusion proteins: A review. Curr Pharm Biotechnol  2023,24(14),1774-1783","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","volume":"167","author":"Sch\u00fctz D.","year":"2020","unstructured":"Sch\u00fctz D.; Ruiz-Blanco Y.B.; M\u00fcnch J.; Kirchhoff F.; Sanchez-Garcia E.; M\u00fcller J.A.; Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev  2020,167,47-65","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2100104","DOI":"10.1002\/adtp.202100104","volume":"4","author":"Panchal D.","year":"2021","unstructured":"Panchal D.; Kataria J.; Patel K.; Crowe K.; Pai V.; Azizogli A.R.; Kadian N.; Sanyal S.; Roy A.; Dodd-o J.; Acevedo-Jake A.M.; Kumar V.A.; Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. Adv Ther  2021,4(10),2100104","journal-title":"Adv Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/v12070693","volume":"12","author":"Barrett C.T.","year":"2020","unstructured":"Barrett C.T.; Dutch R.E.; Viral membrane fusion and the transmembrane domain. Viruses  2020,12(7),693","journal-title":"Viruses"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nsmb.1456","volume":"15","author":"Harrison S.C.","year":"2008","unstructured":"Harrison S.C.; Viral membrane fusion. Nat Struct Mol Biol  2008,15(7),690-698","journal-title":"Nat Struct Mol Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrmicro817","volume":"2","author":"Dimitrov D.S.","year":"2004","unstructured":"Dimitrov D.S.; Virus entry: Molecular mechanisms and biomedical applications. Nat Rev Microbiol  2004,2(2),109-122","journal-title":"Nat Rev Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"Xia S.","year":"2020","unstructured":"Xia S.; Liu M.; Wang C.; Xu W.; Lan Q.; Feng S.; Qi F.; Bao L.; Du L.; Liu S.; Qin C.; Sun F.; Shi Z.; Zhu Y.; Jiang S.; Lu L.; Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res  2020,30(4),343-355","journal-title":"Cell Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","volume":"178","author":"Tang T.","year":"2020","unstructured":"Tang T.; Bidon M.; Jaimes J.A.; Whittaker G.R.; Daniel S.; Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res  2020,178,104792","journal-title":"Antiviral Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0065-3527(05)64007-9","volume":"64","author":"Harrison S.C.","year":"2005","unstructured":"Harrison S.C.; Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res  2005,64,231-261","journal-title":"Adv Virus Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/tra.12389","volume":"17","author":"White J.M.","year":"2016","unstructured":"White J.M.; Whittaker G.R.; Fusion of enveloped viruses in endosomes. Traffic  2016,17(6),593-614","journal-title":"Traffic"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","volume":"363","author":"Liu S.","year":"2004","unstructured":"Liu S.; Xiao G.; Chen Y.; He Y.; Niu J.; Escalante C.R.; Xiong H.; Farmar J.; Debnath A.K.; Tien P.; Jiang S.; Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet  2004,363(9413),938-947","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/22221751.2021.1937329","volume":"10","author":"Yu D.","year":"2021","unstructured":"Yu D.; Zhu Y.; Jiao T.; Wu T.; Xiao X.; Qin B.; Chong H.; Lei X.; Ren L.; Cui S.; Wang J.; He Y.; Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect  2021,10(1),1227-1240","journal-title":"Emerg Microbes Infect"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"pgac198","DOI":"10.1093\/pnasnexus\/pgac198","volume":"1","author":"Jana I.D.","year":"2022","unstructured":"Jana I.D.; Bhattacharya P.; Mayilsamy K.; Banerjee S.; Bhattacharje G.; Das S.; Aditya S.; Ghosh A.; McGill A.R.; Srikrishnan S.; Das A.K.; Basak A.; Mohapatra S.S.; Chandran B.; Bhimsaria D.; Mohapatra S.; Roy A.; Mondal A.; Targeting an evolutionarily conserved \"E-L-L\" motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2. PNAS Nexus  2022,1(5),pgac198","journal-title":"PNAS Nexus"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e2119467119","DOI":"10.1073\/pnas.2119467119","volume":"119","author":"Yang K.","year":"2022","unstructured":"Yang K.; Wang C.; White K.I.; Pfuetzner R.A.; Esquivies L.; Brunger A.T.; Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. Proc Natl Acad Sci USA  2022,119(16),e2119467119","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e2300360120","DOI":"10.1073\/pnas.2300360120","volume":"120","author":"Yang K.","year":"2023","unstructured":"Yang K.; Wang C.; Kreutzberger A.J.B.; White K.I.; Pfuetzner R.A.; Esquivies L.; Kirchhausen T.; Brunger A.T.; Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor. Proc Natl Acad Sci USA  2023,120(13),e2300360120","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/jcb.21790","volume":"104","author":"Chu L.H.M.","year":"2008","unstructured":"Chu L.H.M.; Chan S.H.; Tsai S.N.; Wang Y.; Cheng C.H.K.; Wong K.B.; Waye M.M.Y.; Ngai S.M.; Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): In search of potent SARS-CoV entry inhibitors. J Cell Biochem  2008,104(6),2335-2347","journal-title":"J Cell Biochem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"14064","DOI":"10.1021\/bi049101q","volume":"43","author":"Xu Y.","year":"2004","unstructured":"Xu Y.; Zhu J.; Liu Y.; Lou Z.; Yuan F.; Liu Y.; Cole D.K.; Ni L.; Su N.; Qin L.; Li X.; Bai Z.; Bell J.I.; Pang H.; Tien P.; Gao G.F.; Rao Z.; Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus. Biochemistry  2004,43(44),14064-14071","journal-title":"Biochemistry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"Xia S.","year":"2020","unstructured":"Xia S.; Zhu Y.; Liu M.; Lan Q.; Xu W.; Wu Y.; Ying T.; Liu S.; Shi Z.; Jiang S.; Lu L.; Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol  2020,17(7),765-767","journal-title":"Cell Mol Immunol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1083\/jcb.151.2.425","volume":"151","author":"Armstrong R.T.","year":"2000","unstructured":"Armstrong R.T.; Kushnir A.S.; White J.M.; The transmembrane domain of influenza hemagglutinin exhibits a stringent length requirement to support the hemifusion to fusion transition. J Cell Biol  2000,151(2),425-438","journal-title":"J Cell Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.virol.2003.12.001","volume":"320","author":"Giannecchini S.","year":"2004","unstructured":"Giannecchini S.; Bonci F.; Pistello M.; Matteucci D.; Sichi O.; Rovero P.; Bendinelli M.; The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology  2004,320(1),156-166","journal-title":"Virology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.bbamem.2012.06.002","volume":"1818","author":"Ivankin A.","year":"2012","unstructured":"Ivankin A.; Apell\u00e1niz B.; Gidalevitz D.; Nieva J.L.; Mechanism of membrane perturbation by the HIV-1 gp41 membrane-proximal external region and its modulation by cholesterol. Biochim Biophys Acta Biomembr  2012,1818(11),2521-2528","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1021\/bi501352u","volume":"54","author":"Liao Y.","year":"2015","unstructured":"Liao Y.; Zhang S.M.; Neo T.L.; Tam J.P.; Tryptophan-dependent membrane interaction and heteromerization with the internal fusion peptide by the membrane proximal external region of SARS-CoV spike protein. Biochemistry  2015,54(9),1819-1830","journal-title":"Biochemistry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1517\/14656566.6.3.453","volume":"6","author":"Lazzarin A.","year":"2005","unstructured":"Lazzarin A.; Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother  2005,6(3),453-464","journal-title":"Expert Opin Pharmacother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.1074\/jbc.M609148200","volume":"282","author":"Liu S.","year":"2007","unstructured":"Liu S.; Jing W.; Cheung B.; Lu H.; Sun J.; Yan X.; Niu J.; Farmar J.; Wu S.; Jiang S.; HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem  2007,282(13),9612-9620","journal-title":"J Biol Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","volume":"12","author":"Zhou J.","year":"2022","unstructured":"Zhou J.; Xu W.; Liu Z.; Wang C.; Xia S.; Lan Q.; Cai Y.; Su S.; Pu J.; Xing L.; Xie Y.; Lu L.; Jiang S.; Wang Q.; A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B  2022,12(4),1652-1661","journal-title":"Acta Pharm Sin B"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"42141","DOI":"10.1074\/jbc.M111.254243","volume":"286","author":"Lee K.K.","year":"2011","unstructured":"Lee K.K.; Pessi A.; Gui L.; Santoprete A.; Talekar A.; Moscona A.; Porotto M.; Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem  2011,286(49),42141-42149","journal-title":"J Biol Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"170526","DOI":"10.1016\/j.peptides.2021.170526","volume":"139","author":"Heydari H.","year":"2021","unstructured":"Heydari H.; Golmohammadi R.; Mirnejad R.; Tebyanian H.; Fasihi-Ramandi M.; Moosazadeh Moghaddam M.; Antiviral peptides against Coronaviridae family: A review. Peptides  2021,139,170526","journal-title":"Peptides"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"30376","DOI":"10.1074\/jbc.M804672200","volume":"283","author":"Qi Z.","year":"2008","unstructured":"Qi Z.; Shi W.; Xue N.; Pan C.; Jing W.; Liu K.; Jiang S.; Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem  2008,283(44),30376-30384","journal-title":"J Biol Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"11579","DOI":"10.1039\/c2cc35973a","volume":"48","author":"Shi W.","year":"2012","unstructured":"Shi W.; Cai L.; Lu L.; Wang C.; Wang K.; Xu L.; Zhang S.; Han H.; Jiang X.; Zheng B.; Jiang S.; Liu K.; Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. Chem Commun  2012,48(94),11579-11581","journal-title":"Chem Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s12551-022-00999-7","volume":"14","author":"Negi G.","year":"2022","unstructured":"Negi G.; Sharma A.; Dey M.; Dhanawat G.; Parveen N.; Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: Resolving the mechanisms with biophysical methods. Biophys Rev  2022,14(5),1109-1140","journal-title":"Biophys Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e2210990119","DOI":"10.1073\/pnas.2210990119","volume":"119","author":"Yang K.","year":"2022","unstructured":"Yang K.; Wang C.; Kreutzberger A.J.B.; Ojha R.; Kuivanen S.; Couoh-Cardel S.; Muratcioglu S.; Eisen T.J.; White K.I.; Held R.G.; Subramanian S.; Marcus K.; Pfuetzner R.A.; Esquivies L.; Doyle C.A.; Kuriyan J.; Vapalahti O.; Balistreri G.; Kirchhausen T.; Brunger A.T.; Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein. Proc Natl Acad Sci USA  2022,119(40),e2210990119","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"105571","DOI":"10.1016\/j.antiviral.2023.105571","volume":"212","author":"Hu Y.","year":"2023","unstructured":"Hu Y.; Zhu Y.; Yu Y.; Liu N.; Ju X.; Ding Q.; He Y.; Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides. Antiviral Res  2023,212,105571","journal-title":"Antiviral Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/ncomms4067","volume":"5","author":"Lu L.","year":"2014","unstructured":"Lu L.; Liu Q.; Zhu Y.; Chan K.H.; Qin L.; Li Y.; Wang Q.; Chan J.F.W.; Du L.; Yu F.; Ma C.; Ye S.; Yuen K.Y.; Zhang R.; Jiang S.; Structure-based discovery of middle east respiratory syndrome coronavirus fusion inhibitor. Nat Commun  2014,5(1),3067","journal-title":"Nat Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"Chan D.C.","year":"1997","unstructured":"Chan D.C.; Fass D.; Berger J.M.; Kim P.S.; Core structure of gp41 from the HIV envelope glycoprotein. Cell  1997,89(2),263-273","journal-title":"Cell"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.3390\/ijms21113843","volume":"21","author":"Wang X.","year":"2020","unstructured":"Wang X.; Xia S.; Wang Q.; Xu W.; Li W.; Lu L.; Jiang S.; Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases. Int J Mol Sci  2020,21(11),3843","journal-title":"Int J Mol Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.bbrc.2008.04.044","volume":"371","author":"Lu Y.","year":"2008","unstructured":"Lu Y.; Neo T.L.; Liu D.X.; Tam J.P.; Importance of SARS-CoV spike protein Trp-rich region in viral infectivity. Biochem Biophys Res Commun  2008,371(3),356-360","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1021\/bi400040v","volume":"52","author":"Regula L.K.","year":"2013","unstructured":"Regula L.K.; Harris R.; Wang F.; Higgins C.D.; Koellhoffer J.F.; Zhao Y.; Chandran K.; Gao J.; Girvin M.E.; Lai J.R.; Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids. Biochemistry  2013,52(20),3393-3404","journal-title":"Biochemistry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1128\/JVI.73.3.2469-2480.1999","volume":"73","author":"Salzwedel K.","year":"1999","unstructured":"Salzwedel K.; West J.T.; Hunter E.; A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol  1999,73(3),2469-2480","journal-title":"J Virol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/anie.202008804","volume":"60","author":"Chiliveri S.C.","year":"2021","unstructured":"Chiliveri S.C.; Louis J.M.; Bax A.; Concentration-dependent structural transition of the hiv-1 gp41 mper peptide into \u03b1-helical trimers. Angew Chem Int Ed  2021,60(1),166-170","journal-title":"Angew Chem Int Ed"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.3390\/ijms21165707","volume":"21","author":"Cannalire R.","year":"2020","unstructured":"Cannalire R.; Stefanelli I.; Cerchia C.; Beccari A.R.; Pelliccia S.; Summa V.; SARS-CoV-2 Entry Inhibitors: Small molecules and peptides targeting virus or host cells. Int J Mol Sci  2020,21(16),5707","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/pathogens10121599","volume":"10","author":"D\u00fczg\u00fcne\u015f N.","year":"2021","unstructured":"D\u00fczg\u00fcne\u015f N.; Fernandez-Fuentes N.; Konopka K.; Inhibition of viral membrane fusion by peptides and approaches to peptide design. Pathogens  2021,10(12),1599","journal-title":"Pathogens"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8734","DOI":"10.1021\/acs.jmedchem.8b00890","volume":"61","author":"Wang C.","year":"2018","unstructured":"Wang C.; Zhao L.; Xia S.; Zhang T.; Cao R.; Liang G.; Li Y.; Meng G.; Wang W.; Shi W.; Zhong W.; Jiang S.; Liu K.; De Novo design of \u03b1-helical lipopeptides targeting viral fusion proteins: A promising strategy for relatively broad-spectrum antiviral drug discovery. J Med Chem  2018,61(19),8734-8745","journal-title":"J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s13238-020-00806-7","volume":"12","author":"Wang X.","year":"2021","unstructured":"Wang X.; Xia S.; Zhu Y.; Lu L.; Jiang S.; Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell  2021,12(2),84-88","journal-title":"Protein Cell"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1021\/acs.jmedchem.7b01732","volume":"61","author":"Wang C.","year":"2018","unstructured":"Wang C.; Xia S.; Zhang P.; Zhang T.; Wang W.; Tian Y.; Meng G.; Jiang S.; Liu K.; Discovery of hydrocarbon-stapled short \u03b1-helical peptides as promising middle east respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors. J Med Chem  2018,61(5),2018-2026","journal-title":"J Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1021\/acs.jmedchem.9b00882","volume":"62","author":"Meng G.","year":"2019","unstructured":"Meng G.; Pu J.; Li Y.; Han A.; Tian Y.; Xu W.; Zhang T.; Li X.; Lu L.; Wang C.; Jiang S.; Liu K.; Design and biological evaluation of m -xylene thioether-stapled short helical peptides targeting the hiv-1 gp41 hexameric coiled\u2013coil fusion complex. J Med Chem  2019,62(19),8773-8783","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1021\/jm500763m","volume":"57","author":"Wang C.","year":"2014","unstructured":"Wang C.; Lu L.; Na H.; Li X.; Wang Q.; Jiang X.; Xu X.; Yu F.; Zhang T.; Li J.; Zhang Z.; Zheng B.; Liang G.; Cai L.; Jiang S.; Liu K.; Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: A promising strategy for discovering new antiviral therapeutics. J Med Chem  2014,57(17),7342-7354","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1039\/C6OB01334A","volume":"14","author":"Liang G.","year":"2016","unstructured":"Liang G.; Wang H.; Chong H.; Cheng S.; Jiang X.; He Y.; Wang C.; Liu K.; An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors. Org Biomol Chem  2016,14(33),7875-7882","journal-title":"Org Biomol Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/QAD.0000000000002208","volume":"33","author":"Xu W.","year":"2019","unstructured":"Xu W.; Pu J.; Su S.; Hua C.; Su X.; Wang Q.; Jiang S.; Lu L.; Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS  2019,33(10),1545-1555","journal-title":"AIDS"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e00635-20","DOI":"10.1128\/JVI.00635-20","volume":"94","author":"Zhu Y.","year":"2020","unstructured":"Zhu Y.; Yu D.; Yan H.; Chong H.; He Y.; Design of potent membrane fusion inhibitors against SARS-COV-2, an emerging coronavirus with high fusogenic activity. J Virol  2020,94(14),e00635-20","journal-title":"J Virol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/22221751.2021.1917309","volume":"10","author":"Yu D.","year":"2021","unstructured":"Yu D.; Zhu Y.; Yan H.; Wu T.; Chong H.; He Y.; Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect  2021,10(1),810-821","journal-title":"Emerg Microbes Infect"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e28143","DOI":"10.1002\/jmv.28143","volume":"95","author":"Lan Q.","year":"2023","unstructured":"Lan Q.; Wang L.; Jiao F.; Lu L.; Xia S.; Jiang S.; Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases. J Med Virol  2023,95(1),e28143","journal-title":"J Med Virol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","volume":"5","author":"Xia S.","year":"2019","unstructured":"Xia S.; Yan L.; Xu W.; Agrawal A.S.; Algaissi A.; Tseng C.T.K.; Wang Q.; Du L.; Tan W.; Wilson I.A.; Jiang S.; Yang B.; Lu L.; A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv  2019,5(4),eaav4580","journal-title":"Sci Adv"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e28641","DOI":"10.1002\/jmv.28641","volume":"95","author":"Xia S.","year":"2023","unstructured":"Xia S.; Jiao F.; Wang L.; Yu X.; Lu T.; Fu Y.; Huang Z.; Li X.; Huang J.; Wang Q.; Man Q.; Xiong L.; Jiang S.; Lu L.; SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors. J Med Virol  2023,95(3),e28641","journal-title":"J Med Virol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e01935-20","DOI":"10.1128\/mBio.01935-20","volume":"11","author":"Outlaw V.K.","year":"2020","unstructured":"Outlaw V.K.; Bovier F.T.; Mears M.C.; Cajimat M.N.; Zhu Y.; Lin M.J.; Addetia A.; Lieberman N.A.P.; Peddu V.; Xie X.; Shi P.Y.; Greninger A.L.; Gellman S.H.; Bente D.A.; Moscona A.; Porotto M.; Inhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. MBio  2020,11(5),e01935-20","journal-title":"MBio"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.3390\/ijms222111869","volume":"22","author":"Lan Q.","year":"2021","unstructured":"Lan Q.; Wang C.; Zhou J.; Wang L.; Jiao F.; Zhang Y.; Cai Y.; Lu L.; Xia S.; Jiang S.; 25-Hydroxycholesterol-Conjugated EK1 peptide with potent and broad-spectrum inhibitory activity against SARS-CoV-2, its variants of concern, and other human coronaviruses. Int J Mol Sci  2021,22(21),11869","journal-title":"Int J Mol Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41392-021-00698-x","volume":"6","author":"Zhu Y.","year":"2021","unstructured":"Zhu Y.; Yu D.; Hu Y.; Wu T.; Chong H.; He Y.; SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther  2021,6(1),294","journal-title":"Signal Transduct Target Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/v14030549","volume":"14","author":"Lan Q.","year":"2022","unstructured":"Lan Q.; Chan J.F.W.; Xu W.; Wang L.; Jiao F.; Zhang G.; Pu J.; Zhou J.; Xia S.; Lu L.; Yuen K.Y.; Jiang S.; Wang Q.; A palmitic acid-conjugated, peptide-based pan-cov fusion inhibitor potently inhibits infection of SARS-CoV-2 omicron and other variants of concern. Viruses  2022,14(3),549","journal-title":"Viruses"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"9916","DOI":"10.1002\/anie.201805184","volume":"57","author":"She F.","year":"2018","unstructured":"She F.; Teng P.; Peguero-Tejada A.; Wang M.; Ma N.; Odom T.; Zhou M.; Gjonaj E.; Wojtas L.; van der Vaart A.; Cai J.; De novo left-handed synthetic peptidomimetic foldamers. Angew Chem Int Ed  2018,57(31),9916-9920","journal-title":"Angew Chem Int Ed"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"10552","DOI":"10.1021\/acs.joc.0c00996","volume":"85","author":"Sang P.","year":"2020","unstructured":"Sang P.; Shi Y.; Higbee P.; Wang M.; Abdulkadir S.; Lu J.; Daughdrill G.; Chen J.; Cai J.; Rational design and synthesis of right-handed  -Sulfono-\u03b3-AApeptide helical foldamers as potent inhibitors of protein\u2013protein interactions. J Org Chem  2020,85(16),10552-10560","journal-title":"J Org Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.accounts.0c00482","volume":"53","author":"Sang P.","year":"2020","unstructured":"Sang P.; Shi Y.; Huang B.; Xue S.; Odom T.; Cai J.; Sulfono-\u03b3-aapeptides as helical mimetics: Crystal structures and applications. Acc Chem Res  2020,53(10),2425-2442","journal-title":"Acc Chem Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1021\/acscentsci.3c00313","volume":"9","author":"Xue S.","year":"2023","unstructured":"Xue S.; Xu W.; Wang L.; Wang X.; Duan Q.; Calcul L.; Wang S.; Liu W.; Sun X.; Lu L.; Jiang S.; Cai J.; An HR2-Mimicking sulfonyl-\u03b3-aapeptide is a potent pan-coronavirus fusion inhibitor with strong blood\u2013brain barrier permeability, long half-life, and promising oral bioavailability. ACS Cent Sci  2023,9(5),1046-1058","journal-title":"ACS Cent Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tips.2014.06.004","volume":"35","author":"Wisskirchen K.","year":"2014","unstructured":"Wisskirchen K.; Lucifora J.; Michler T.; Protzer U.; New pharmacological strategies to fight enveloped viruses. Trends Pharmacol Sci  2014,35(9),470-478","journal-title":"Trends Pharmacol Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"Jackson C.B.","year":"2022","unstructured":"Jackson C.B.; Farzan M.; Chen B.; Choe H.; Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol  2022,23(1),3-20","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3892\/ijmm.2023.5222","volume":"51","author":"Zheng L.","year":"2023","unstructured":"Zheng L.; Zhang L.; Zheng Y.; An J.; Wen G.; Jin H.; Tuo B.; Digestive system infection by SARS-CoV-2: Entry mechanism, clinical symptoms and expression of major receptors (Review). Int J Mol Med  2023,51(3),19","journal-title":"Int J Mol Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri1129","volume":"3","author":"Ma\u00f1es S.","year":"2003","unstructured":"Ma\u00f1es S.; del Real G.; Mart\u00ednez-A C.; Pathogens: raft hijackers. Nat Rev Immunol  2003,3(7),557-568","journal-title":"Nat Rev Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","volume":"106","author":"Ingallinella P.","year":"2009","unstructured":"Ingallinella P.; Bianchi E.; Ladwa N.A.; Wang Y.J.; Hrin R.; Veneziano M.; Bonelli F.; Ketas T.J.; Moore J.P.; Miller M.D.; Pessi A.; Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA  2009,106(14),5801-5806","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"e60302","DOI":"10.1371\/journal.pone.0060302","volume":"8","author":"Hollmann A.","year":"2013","unstructured":"Hollmann A.; Matos P.M.; Augusto M.T.; Castanho M.A.R.B.; Santos N.C.; Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. PLoS One  2013,8(4),e60302","journal-title":"PLoS One"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"e00831-17","DOI":"10.1128\/JVI.00831-17","volume":"91","author":"Ding X.","year":"2017","unstructured":"Ding X.; Zhang X.; Chong H.; Zhu Y.; Wei H.; Wu X.; He J.; Wang X.; He Y.; Enfuvirtide (T20)-Based lipopeptide is a potent HIV-1 Cell fusion inhibitor: Implications for viral entry and inhibition. J Virol  2017,91(18),e00831-17","journal-title":"J Virol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"114336","DOI":"10.1016\/j.ejmech.2022.114336","volume":"236","author":"Wang H.","year":"2022","unstructured":"Wang H.; Wang X.; Li J.; Li Q.; Feng S.; Lu L.; Wang C.; Jiang S.; Design of artificial \u03b1-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors. Eur J Med Chem  2022,236,114336","journal-title":"Eur J Med Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.abf4896","volume":"371","author":"de Vries R.D.","year":"2021","unstructured":"de Vries R.D.; Schmitz K.S.; Bovier F.T.; Predella C.; Khao J.; Noack D.; Haagmans B.L.; Herfst S.; Stearns K.N.; Drew-Bear J.; Biswas S.; Rockx B.; McGill G.; Dorrello N.V.; Gellman S.H.; Alabi C.A.; de Swart R.L.; Moscona A.; Porotto M.; Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science  2021,371(6536),1379-1382","journal-title":"Science"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1080\/22221751.2022.2098060","volume":"11","author":"Zhu Y.","year":"2022","unstructured":"Zhu Y.; Dong X.; Liu N.; Wu T.; Chong H.; Lei X.; Ren L.; Wang J.; He Y.; SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. Emerg Microbes Infect  2022,11(1),1819-1827","journal-title":"Emerg Microbes Infect"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"14093","DOI":"10.1073\/pnas.1002713107","volume":"107","author":"Bird G.H.","year":"2010","unstructured":"Bird G.H.; Madani N.; Perry A.F.; Princiotto A.M.; Supko J.G.; He X.; Gavathiotis E.; Sodroski J.G.; Walensky L.D.; Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci USA  2010,107(32),14093-14098","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1016\/j.bmcl.2013.07.056","volume":"23","author":"Higgins C.D.","year":"2013","unstructured":"Higgins C.D.; Koellhoffer J.F.; Chandran K.; Lai J.R.; C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: Effects of conjugation to cholesterol and side chain\u2013side chain crosslinking. Bioorg Med Chem Lett  2013,23(19),5356-5360","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1039\/C8OB02159G","volume":"16","author":"Bolarinwa O.","year":"2018","unstructured":"Bolarinwa O.; Zhang M.; Mulry E.; Lu M.; Cai J.; Sulfono-\u03b3-AA modified peptides that inhibit HIV-1 fusion. Org Biomol Chem  2018,16(42),7878-7882","journal-title":"Org Biomol Chem"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"17486","DOI":"10.1021\/acs.jmedchem.1c01681","volume":"64","author":"Zheng M.","year":"2021","unstructured":"Zheng M.; Cong W.; Peng H.; Qing J.; Shen H.; Tang Y.; Geng C.; Chen S.; Zou Y.; Zhang W.D.; Hu H.G.; Li X.; Stapled peptides targeting SARS-CoV-2 Spike Protein HR1 inhibit the fusion of virus to its cell receptor. J Med Chem  2021,64(23),17486-17495","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"8779","DOI":"10.1039\/D2RA07356K","volume":"13","author":"Tsuji K.","year":"2023","unstructured":"Tsuji K.; Baffour-Awuah Owusu K.; Miura Y.; Ishii T.; Shinohara K.; Kobayakawa T.; Emi A.; Nakano T.; Suzuki Y.; Tamamura H.; Dimerized fusion inhibitor peptides targeting the HR1\u2013HR2 interaction of SARS-CoV-2. RSC Advances  2023,13(13),8779-8793","journal-title":"RSC Advances"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/cbic.201900187","volume":"20","author":"Kobayakawa T.","year":"2019","unstructured":"Kobayakawa T.; Ebihara K.; Honda Y.; Fujino M.; Nomura W.; Yamamoto N.; Murakami T.; Tamamura H.; Dimeric C34 Derivatives linked through disulfide bridges as New HIV-1 fusion inhibitors. ChemBioChem  2019,20(16),2101-2108","journal-title":"ChemBioChem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1039\/b914339b","volume":"39","author":"Apostolovic B.","year":"2010","unstructured":"Apostolovic B.; Danial M.; Klok H.A.; Coiled coils: attractive protein folding motifs for the fabrication of self-assembled, responsive and bioactive materials. Chem Soc Rev  2010,39(9),3541-3575","journal-title":"Chem Soc Rev"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.1057453","volume":"291","author":"Root M.J.","year":"2001","unstructured":"Root M.J.; Kay M.S.; Kim P.S.; Protein design of an HIV-1 entry inhibitor. Science  2001,291(5505),884-888","journal-title":"Science"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1039\/C5SC02220G","volume":"6","author":"Wang C.","year":"2015","unstructured":"Wang C.; Lai W.; Yu F.; Zhang T.; Lu L.; Jiang X.; Zhang Z.; Xu X.; Bai Y.; Jiang S.; Liu K.; De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. Chem Sci  2015,6(11),6505-6509","journal-title":"Chem Sci"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1039\/C5SC04046A","volume":"7","author":"Lai W.","year":"2016","unstructured":"Lai W.; Wang C.; Yu F.; Lu L.; Wang Q.; Jiang X.; Xu X.; Zhang T.; Wu S.; Zheng X.; Zhang Z.; Dong F.; Jiang S.; Liu K.; An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chem Sci (Camb)  2016,7(3),2145-2150","journal-title":"Chem Sci (Camb)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"32161","DOI":"10.1038\/srep32161","volume":"6","author":"Wang C.","year":"2016","unstructured":"Wang C.; Li X.; Yu F.; Lu L.; Jiang X.; Xu X.; Wang H.; Lai W.; Zhang T.; Zhang Z.; Ye L.; Jiang S.; Liu K.; Site-specific isopeptide bridge tethering of chimeric gp41 N-terminal heptad repeat helical trimers for the treatment of HIV-1 Infection. Sci Rep  2016,6(1),32161","journal-title":"Sci Rep"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1002\/pro.688","volume":"20","author":"Harrison J.S.","year":"2011","unstructured":"Harrison J.S.; Higgins C.D.; Chandran K.; Lai J.R.; Designed protein mimics of the Ebola virus glycoprotein GP2 \u03b1-helical bundle: Stability and pH effects. Protein Sci  2011,20(9),1587-1596","journal-title":"Protein Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/pro.2578","volume":"24","author":"Clinton T.R.","year":"2015","unstructured":"Clinton T.R.; Weinstock M.T.; Jacobsen M.T.; Szabo-Fresnais N.; Pandya M.J.; Whitby F.G.; Herbert A.S.; Prugar L.I.; McKinnon R.; Hill C.P.; Welch B.D.; Dye J.M.; Eckert D.M.; Kay M.S.; Design and characterization of ebolavirus  prehairpin intermediate mimics as drug targets. Protein Sci  2015,24(4),446-463","journal-title":"Protein Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/v9090255","volume":"9","author":"Sun Y.","year":"2017","unstructured":"Sun Y.; Zhang H.; Shi J.; Zhang Z.; Gong R.; Identification of a novel inhibitor against middle east respiratory syndrome coronavirus. Viruses  2017,9(9),255","journal-title":"Viruses"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1021\/acs.jmedchem.1c00258","volume":"65","author":"Wang C.","year":"2022","unstructured":"Wang C.; Xia S.; Wang X.; Li Y.; Wang H.; Xiang R.; Jiang Q.; Lan Q.; Liang R.; Li Q.; Huo S.; Lu L.; Wang Q.; Yu F.; Liu K.; Jiang S.; Supercoiling structure-based design of a trimeric coiled-coil peptide with high potency against HIV-1 and human \u03b2-coronavirus infection. J Med Chem  2022,65(4),2809-2819","journal-title":"J Med Chem"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/v14030597","volume":"14","author":"Xing L.","year":"2022","unstructured":"Xing L.; Xu X.; Xu W.; Liu Z.; Shen X.; Zhou J.; Xu L.; Pu J.; Yang C.; Huang Y.; Lu L.; Jiang S.; Liu S.; A Five-Helix-Based SARS-CoV-2 fusion inhibitor targeting heptad repeat 2 domain against SARS-CoV-2 and its variants of concern. Viruses  2022,14(3),597","journal-title":"Viruses"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-981-16-8702-0_2","volume":"1366","author":"Pu J.","year":"2022","unstructured":"Pu J.; Wang Q.; Jiang S.; Peptide-Based HIV entry inhibitors. Adv Exp Med Biol  2022,1366,15-26","journal-title":"Adv Exp Med Biol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1074\/jbc.RA118.003538","volume":"293","author":"Yu D.","year":"2018","unstructured":"Yu D.; Ding X.; Liu Z.; Wu X.; Zhu Y.; Wei H.; Chong H.; Cui S.; He Y.; Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial\u2013approved membrane fusion inhibitor. J Biol Chem  2018,293(33),12703-12718","journal-title":"J Biol Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673265694231113061842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223808\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673265694231113061842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T14:42:12Z","timestamp":1748961732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223808\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":101,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673265694231113061842","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}